CA2881992A1 - Enteric coated multiparticulate controlled release peppermint oil composition and related methods - Google Patents

Enteric coated multiparticulate controlled release peppermint oil composition and related methods Download PDF

Info

Publication number
CA2881992A1
CA2881992A1 CA2881992A CA2881992A CA2881992A1 CA 2881992 A1 CA2881992 A1 CA 2881992A1 CA 2881992 A CA2881992 A CA 2881992A CA 2881992 A CA2881992 A CA 2881992A CA 2881992 A1 CA2881992 A1 CA 2881992A1
Authority
CA
Canada
Prior art keywords
cores
peppermint oil
multiparticulate composition
enteric
enteric coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2881992A
Other languages
French (fr)
Other versions
CA2881992C (en
Inventor
Syed M. Shah
Daniel HASSAN
Fred Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
ZxPharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZxPharma LLC filed Critical ZxPharma LLC
Publication of CA2881992A1 publication Critical patent/CA2881992A1/en
Application granted granted Critical
Publication of CA2881992C publication Critical patent/CA2881992C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • A61K9/5057Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534Mentha (mint)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1658Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Abstract

A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders.

Description

ENTERIC COATED MULTIPARTICULATE CONTROLLED RELEASE PEPPERMINT
OIL COMPOSITION AND RELATED METHODS
Inventors: Syed Shah, Daniel Hassan, and Fred Hassan Cross-Reference to Related Application [0001]
This is a continuation-in-part of U.S. application 13/367,747, filed February 7, 2012, which claims priority to U.S. provisional application 61/486,523, filed May 16, 2011 and U.S. provisional application 61/441,716, filed February 11, 2011. This also claims priority to U.S. provisional application 61/815,073, filed April 23, 2013 and U.S. provisional application 61/880,294, filed September 20, 2013. Each of these prior applications is incorporated by reference in its entirety.
Field of the Invention
[0002] The invention relates to enteric coated multiparticulate compositions, and, more particularly, to enteric coated multiparticulate compositions containing peppermint oil.
Background
[0003]
Peppermint oil is used to address gastrointestinal problems because it inhibits the smooth muscles in the gastrointestinal tract from contracting.
Unfortunately, however, if peppermint oil is released in the stomach, it is absorbed quickly and can upset the stomach. To overcome this problem, others have developed enteric coated peppermint oil formulations that allow the peppermint oil to pass into the intestines before it is released.
[0004] In conventional enteric coated peppermint oil formulations, the peppermint oil is loaded into .a hollow capsule that is enteric coated. The enteric coating prevents the capsule from dissolving in the stomach, but allows the capsule to dissolve in the intestines and release the peppermint oil.

[0 0 0 5]
Single-unit enteric coated peppermint oil capsules such as these have several drawbacks.
First, the dose of peppermint oil that is actually absorbed by the intestines of the person taking the capsule is unpredictable. One of the reasons for this is that, when the capsule dissolves, it quickly dumps all of the peppermint oil into the same area of the intestines, which is problematic because peppermint oil is not very water soluble.
Another of the reasons for this is that food in the gastrointestinal tract affects the amount of peppermint oil absorbed.
[0006] A
second drawback associated with single-unit enteric coated peppermint oil capsules is that the onset of action of the peppermint oil is unreliable. The primary factor delaying the onset of action is the amount of time the capsule spends in the stomach, which ranges over several hours and depends on the amount of food in the stomach. In order to get a reliable onset of action, one should take the capsules on an empty stomach.
But because some gastrointestinal disorders flare up after a meal, people often want to treat the flare up immediately.
Accordingly, the single-unit enteric coated capsules are not ideal for treating acute gastrointestinal flare ups that are triggered by food.
[0007] A
third drawback associated with single-unit enteric coated peppermint oil capsules is the fact that peppermint oil is volatile. If the capsules are shipped or stored much above room temperature for extended periods of time, the peppermint oil can evaporate and permeate the capsule.
[0008] We surmised that these problems could be addressed by developing enteric coated multiparticulate compositions containing peppermint oil, but found that it is difficult to do so because peppermint oil is very volatile. If multiparticulate cores containing peppermint oil are heated or stored for extended periods, much above room temperature, the volatile components of the peppermint oil leave the cores and permeate the enteric coating.
This made it difficult to process the cores, especially when it came time to cure the enteric coating on the cores at elevated temperatures.
[0009] In U.S. patent publication 2012/0207842, we described making enteric coated multiparticulate L-menthol compositions.
In order to prevent the L-menthol from sublimating as the cores were being processed, we resorted to low temperature processing techniques.
The L-menthol multiparticulate compositions described in that application provided the release profile that we desired and worked well for some applications, but were not optimized for all applications.
[0010] We have identified a need for a peppermint oil composition that avoids the drawbacks associated with single-unit enteric coated capsules and can be made using conventional room temperature processing techniques Summary [0011] A
multiparticulate composition that embodies these principles comprises a plurality of individual enteric coated cores that include a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel . The microcrystalline cellulose functions as a release controlling polymer for the peppermint oil, preventing dose dumping and stabilizing the peppermint oil while the cores are being processed.
[0012] In another composition aspect of the invention, the multiparticulate composition comprises a plurality of individual enteric coated cores containing about 15% w/w to about 40% w/w peppermint oil, about 35% w/w to about 75% w/w microcrystalline cellulose, and about 2% w/w to about 15% w/w methylcellulose, wherein the % w/w is the % w/w of the enteric coated cores.

[0013] In some cases, including a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings may be advantageous because the proteinaceous subcoating layer further enhances the stability of the peppermint oil.
The continuous proteinaceous subcoating is adapted to prevent the peppermint oil from mixing with the enteric coating.
[0014] Some preferred proteinaceous subcoatings have the following attributes: the subcoating may comprise a gelatin film adhered to the core and/or the subcoating may comprise a dried proteinaceous gel.
[0015]
The enteric coating may have a glass transition temperature higher than a standard boiling point of the peppermint oil.
[0016] In a particular embodiment, the enteric coated cores release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N HC1 solution and, subsequently, no less than about 85% of the peppermint oil within about eight hours of being placed in a substantially neutral pH environment.
[0017]
Preferably, the enteric coated cores are spheroidal and not more than 3 mm in diameter.
[0018] In a first method aspect of the invention, a method of making a multiparticulate composition comprises blending peppermint oil, microcrystalline cellulose, a hydrogel-forming polymer, and water to form a wet mass including a hydrophobic phase containing the peppermint oil dispersed in a gel formed by the microcrystalline cellulose and a hydrophilic phase containing the hydroxypropyl methylcellulose and water;
extruding the wet mass to form an extrudate; dividing the extrudate into individual wet cores;
removing water from the hydrophilic phase in the wet cores to form dried cores; and applying an enteric coating to the dried cores.
[0019]
The method may further comprise coating the dried cores with a liquid proteinaceous material and drying the liquid proteinaceous material to form sub-coated cores prior to applying the enteric coating. The liquid proteinaceous material may comprises gelatin. A
particular example of the liquid proteinaceous material is a solution containing at least about 50% gelatin.
[0020]
The dried .cores may be coated with the liquid proteinaceous material by spraying the liquid proteinaceous material onto the dried cores.
[0021]
Once made, the enteric coated cores are preferably spheroidal and not more than 3 mm in diameter.
[0022]
Removing water from the hydrophilic phase in the wet cores to form dried cores is preferably achieved without substantially removing peppermint oil.
[0023] In a second method aspect of the invention, a method of treating a gastrointestinal disorder in a subject comprises administering to the subject a multiparticulate composition comprising a plurality of individual enteric coated cores that include a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a methylcellulose-based gel.
Administering is preferably performed enterally. If desired, the multiparticulate composition may be blended with an acidic vehicle prior to being administered.
[0024]
These and other aspects, embodiments, and advantages of the invention will be better understood by reviewing the accompanying figures and the Detailed Description of Preferred Embodiments.
Brief Description of the Drawings [0025] FIG. 1 is a graph showing the results of an accelerated stability assay for a, multiparticulate composition according to an embodiment of the invention stored at 40 degrees C and 75% relative humidity for four weeks; and [0026]
FIG. 2 is a graph showing the results of a two-stage dissolution test for a multiparticulate composition according to an embodiment of the invention after the composition was stored at 40 degrees C and 75% relative humidity.
Detailed Description of Preferred Embodiments = [0027] In the Summary and Detailed Description of Preferred Embodiments reference is made to particular features (including method steps) of the invention. It is to be understood that the disclosure of the invention in this specification includes all possible combinations of such particular features, even if those combinations are not explicitly disclosed together.
For example, where a particular feature is disclosed in the context of a particular aspect or embodiment of the invention, that feature can also be used, to the extent possible, in combination with and/or in the context of other particular aspects and embodiments of the invention, and in the invention generally.
[0028]
The term "comprises" is used herein to mean that other ingredients, steps, etc. are optionally present.
When reference is made herein to a method comprising two or more defined steps, the steps can be carried in any order or simultaneously (except where the context excludes that possibility), and the method can include one or more steps which are carried out before any of the defined steps, between two of the defined steps, or after all of the defined steps (except where the context excludes that possibility).
[0029]
In this section, the invention will be described more fully with reference to its preferred embodiments.
The invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
Rather, these embodiments are provided so that this disclosure will convey preferred embodiments of the invention to those skilled in the art.
[0030]
Because peppermint oil is so volatile, it is difficult to make peppermint oil-containing dosage forms.
Conventional processing methods for making pharmaceutical dosage forms involve heating, which conventional wisdom suggests one should avoid when using volatile ingredients. We found that it is very difficult to make stable multiparticulate peppermint oil-containing compositions, for this and other reasons.
[0031] Microcrystalline cellulose, or "MCC," is a pharmaceutical excipient that is widely used as a disintegrant in solid oral dosage forms. MCC promotes the breakup of tablets in aqueous environments to enhance drug release. It does this by wicking moisture through the pores of the tablet, weakening the tablet and causing it to disintegrate. Since MCC is used as a disintegrant, its causes the active ingredients in the solid oral dosage form to be released faster than they would otherwise be released.
[0032] We found that MCC also functions as a release-controlling polymer for peppermint oil and developed multiparticulate enteric coated peppermint oil compositions using MCC as a release-controlling polymer in the core. The MCC
gradually releases the peppermint oil into the intestines rather than quickly dumping the entire dose in a small region of the intestines. Accordingly, the MCC in our multiparticulate peppermint oil compositions performs the opposite function of a disintegrant and overcomes the dose-dumping drawback held by the conventional single-unit enteric coated capsules.
[0033] The multiparticulate composition aspect of the inventions is first described. The multiparticulate composition is adapted to carry peppermint oil to the intestines and includes a plurality of particulates that are preferably spheroidal in shape and are sized to fit through the pyloric sphincter when it is in a relaxed state. The diameter of each particulate is preferably in the range of about 0.1 mm to about 3 mm or, about 1 mm to about 2.5 mm, or less than about 1.4 mm.
Particulates of this diameter are advantageous because they can fit through the pyloric sphincter and do not remain in the stomach as long as single-unit capsules, thereby providing a more reliable onset of action.
[0034] The multiparticulate composition includes a plurality of individual peppermint-oil containing cores that are each enteric coated. The enteric coating allows the individual cores to pass through the stomach without releasing a substantial amount of peppermint oil. In the pH of the intestines, the enteric coating dissolves, exposing the cores and allowing peppermint oil to be released.
[0035] The core contains the primary active ingredient peppermint oil, but may also contain other secondary active ingredients such as one or more other terpene-based substances such as terpenes, terpenoids, and/or essential oils.
Terpene-based substances that may be used as secondary active ingredients include but are not limited to L-menthol, caraway oil, orange oil, ginger oil, turmeric oil, curcumin oil, and fennel oil, among others.
[0036]
Alternatively, the secondary active ingredient may be a non-terpene-based substance that helps relieve gastrointestinal disorder symptoms from their various actions.
Examples of non-terpene secondary active ingredients include, but are not limited to, polyphenols such as green tea extracts and aloe vera powder, proton pump inhibitors, anti-inflammatories, and immune suppressors among others.

[0 0 3 7 ]
Essential oils such as peppermint oil, caraway oil, orange oil, fennel oil, etc. are liquid at room temperature.
They are usually formulated as liquids in a capsule, with an enteric-coating over the capsule. We discovered that essential oils can be mixed with a cellulosic filler and a binder to make a dough or wet mass, but the dough formed by simply mixing these materials together does not produce a core with the desired strength for subcoating and further processing. By adding water to the wet mass, we produced cores containing peppermint oil that were robust enough for subsequent processing.
[0038] The core may also contain one or more antioxidants that can maintain the purity of the peppermint oil and other active ingredients if used.
This is useful because peppermint oil can oxidize to form undesirable derivatives.
Examples of antioxidants that may be used include, but are not limited to tocopherol (vitamin E,) BHT (butylated hydroxy toluene), BHA
(butylayted hydroxy anisole), and ascorbic acid.
[0039] In the core, peppermint oil is combined with MCC and a hydrogel forming polymer binder such as s a cellulose-based, starch-based, and/or povidone-based binder. It is to be understood that "cellulose-based," "starch-based" binders, and "povidone-based" binders includes cellulose, starch, and povidone derivatives. When mixed with water, the binder swells to form a hydrogel matrix. In contrast, MCC and peppermint oil are hydrophobic.
Examples of cellulouse-based binders include methylcellulose based polymers, including, for example, methylcellulose and hydroxypropyl methylcellulose.
Methylcellulose is particularly preferred for use in the composition.
[0040]
When water is added to the core during processing, these materials separate into a hydrophobic phase and hydrophilic phase. The hydrophobic phase contains peppermint oil dispersed in the microcrystalline cellulose-based gel and the hydrophilic phase contains the hydrogel. The peppermint oil is therefore, dispersed throughout the hydrophobic phase, which is in contact with the hydrophilic phase.
[0041] One of the advantageous of dispersing the peppermint oil in MCC is that it allows excess water to be removed from the cores without also removing a substantial amount of the peppermint oil. Conventional drying techniques would cause the peppermint oil in the core to evaporate with the water. Thus, by making the core to include a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a methylcellulose-based polymer, the core can be processed without risking substantial loss of the peppermint oil.
[0042] The core may also include pharmaceutically acceptable fillers, stabilizers, binders, surfactants, processing aids, and/or disintegrants. By way of example only, suitable materials for performing these functions are provided.
[0043]
Preferred fillers include cellulosic filler materials such as microcrystalline cellulose, dibasic calcium phosphate, and/or another pharmaceutically acceptable filler.
[0044]
Preferred binders include cellulosic water soluble polymers such as methylcellulose, starch, hydroxypropyl cellulose, gelatin, polyvinylpyrrolidone, polyethylene glycol, and/or another pharmaceutically acceptable binder.
[0045] In some cases, it may be advantageous to include a surfactant as a solubilizing agent. If used, preferred solubulizing agents include but are not limited to polysorbate 80 and/or sodium lauryl sulfate.
Advantageously when polysorbate 80 is used, it may also enhance absorption of terpene-based active ingredients into the plasma.

[00 4 6]
Suitable processing aids include pharmaceutically acceptable processing aids for improving the flowability of the core materials during processing.
Preferred processing aids include, but are not limited to, colloidal silicon dioxide, talc, magnesium stearate, stearin, and/or another pharmaceutically acceptable processing aid.
[0047]
Preferred disintegrants include, but are not limited to, croscarmellose sodium, polyvinylpyrrolidone (crospovidone) sodium starch glycolate, and/or another pharmaceutically acceptable processing aid.
[0048] In a particularly preferred embodiment of the multiparticulate composition, the cores contain about 15% w/w to about 40% w/w peppermint oil, about 35% w/w to about 75% w/w microcrystalline cellulose, and about 2% w/w to about 15% w/w methylcellulose, wherein the % w/w is the % w/w of the enteric coated cores.
[0049]
Because it is often desirable to be able to ship products in non-refrigerated vehicles and store them for a long period of time, we preferred for our peppermint oil-containing multiparticulate composition to be stable when stored at 40 degrees C and 75% relative humidity, from between 1 day to 30 days, and even longer.
This would also be useful if the multiparticulate composition is distributed in regions in climate zone IV.
[0050] While developing multiparticulate compositions containing terpene-based active ingredients, however, we found that volatile ingredients sometimes penetrated the conventional subcoating materials we used to separate the cores form their enteric coatings. Because of this, the active ingredients would come in contact with the enteric coating if the temperature was elevated (25 degrees C - 50 degrees C) or the composition was stored for a long period of time.
This somewhat reduced the effectiveness of the enteric coating and amount of active ingredient in the core.
[0051] We solved this problem by developing a new subcoating material that may be applied to the finished core and prevents volatile active ingredients in the core from leaving the core and permeating the enteric coating at elevated temperatures.
The subcoating includes a proteinaceous material that is applied along each core's exterior surface to form a substantially continuous thin film that forms a barrier between the core and the enteric coating that is applied after the subcoating.
[0052]
Examples of proteinaceous materials that may be used in the subcoating include proteins such as, but not limited to casein, whey protein, soy protein, and various types of gelatin (Type A, Type B or derivatives of gelatin) or proteinaceous materials that have protein-like structures. A
particularly preferred material used to form the subcoating is a solution containing at least about 50% of the proteinaceous material dispersed in a solvent.
The solvent is preferably, but not necessarily water. A
particularly preferred proteinaceous material is Type A gelatin.
[0053]
The proteinaceous subcoating is preferably applied to the core in liquid form and subsequently dried on the core.
When dry, the subcoating adheres to the core. Examples of the liquid form of the proteinaceous subcoating material include melts and gels.
When dry, the subcoating forms a continuous film over the core and provides a barrier between the core and enteric coating.
[0054]
Gelatin typically melts at about 35 degrees C, which is below the normal human body temperature of about 37 degrees C.
Given this, one might expect that, if a multiparticulate composition, including a gelatin subcoating, is heated above 35 degrees C, the subcoating will melt and release the active ingredients from the core. We observed, however, that gelatin subcoated multiparticulate compositions did not release the terpene-based active ingredients from the core even when heated above 35 degrees C.
This is a particularly unexpected result that provides numerous advantages.
[0055]
Because the proteinaceous subcoating prevents volatile peppermint oil from being released from the core even when heating above the melting point of the proteinaceous material, by applying the proteinaceous subcoating, one does not have to avoid heating the subcoated cores during processing.
One scenario in which this is advantageous is when the enteric coating is applied.
Enteric coating polymers have a glass transition temperature (Tg) that is often above 35 degrees C.
After being applied to a core, enteric coated particulates are preferably heated above Tg so that the enteric coating polymer can cure, thereby achieving optimum enteric protection of the core. Thus, using the proteinaceous subcoating between the core and enteric coating allows one to achieve optimum enteric protection without releasing the peppermint oil from the core.
[0056]
The subcoating may be applied to the core as a gelatin-containing subcoating solution. The solvent may be any solvent in which gelatin is soluble, such as water. In a preferred embodiment, the subcoating solution comprises about 5%
to about 30% w/w gelatin and about 70% to about 95% solvent.
When the subcoating solution is allowed to dry around the core, the solvent evaporates, leaving a thin gelatin film that adheres to the core and forms a barrier between the core and enteric coating.
The gelatin film subcoating is preferably about 3.5%
w/w to about 35% w/w of the enteric coated particulates.
Surprisingly, in our experiments, drying the cores containing peppermint oil and water, at about 15 degrees C to about 25 degrees C did not result in significant loss of the peppermint oil as the water was being removed by fluid bed drying.
[0057]
The enteric coating is applied over each core, or, if a subcoating is used, over the subcoating. In a preferred embodiment, the enteric coating is about 2% w/w to about 35% w/w of the enteric coated particulate. A preferred enteric coating material is a methacrylic acid based material such as a methacrylic acid based co-polymer.
These materials may be combined with other materials such as plasticizers for forming an enteric coating solution. In a typical embodiment, the enteric coating solution comprises about 5% w/w to about 35% w/w water, and the enteric-coated dried multiparticulates contain 0.5% w/w to about 5% w/w plasticizer, about 0.05% w/w to about
5% w/w anti-adherent, and about 2% w/w to about 35% w/w methacrylic acid copolymer. By way of example only, a suitable plasticizer is triethyl citrate and a suitable anti-adherent is PlasACRYIXD T20 (Emerson Resources, Inc., Norristown, PA).
The enteric coating is preferably about 3.5% w/w to about 35% w/w of the enteric coated particulates.
[0058]
The enteric-coated particulates may be coated with a finish coat. The finish coat is used, for example, to overcome the mucoadhesive properties of some enteric coating materials, which make the multiparticulates stick together during processing, storage, or dispensing through a tube for enteral feeding. The finish coat is preferably a cellulosic derivative such as HPMC (hydroxylpropyl methylcellulose), HPC (hydroxyl propyl cellulose), CMC (carboxy methylcellulose), or another pharmaceutically acceptable finish coating material. When used, the finish coat is preferably about 1% to 10% w/w of the finished multiparticulate.
[0059] A
particularly preferred finish coat material is HPMC
because is not mucoadhesive. As such, it prevents the multiparticulates from sticking to the stomach wall as well as food in the stomach. This allows the multiparticulates to reach the intestines quickly, making the onset of action more reliable than the single-unit capsules.
[0060]
The release profile of peppermint oil in the body can be varied to treat different disorders.
Peppermint oil can be used to treat a plethora of gastrointestinal disorders such as irritable bowel syndrome, inflammatory bowel disease, gastroparesis, and functional dyspepsia, but it is best to release the active ingredients at a certain point in the gastrointestinal tract to optimally treat each disorder.
[0061] To treat gastrointestinal disorders associated with irritable bowel syndrome, the multiparticulate composition is formulated to minimize the amount of peppermint oil released into the stomach and colon, so that most of it is released in the small intestine.
Preferably, 20% or less of the peppermint oil is released into the stomach and 20% or less of the peppermint oil is released into the colon.
Also, in many instances such as IBS, the peppermint oil is preferably gradually released over the course of about 4 to about 8 hours after the multiparticulates pass the pyloric sphincter into the small intestine in order to deliver the active ingredients locally in the small intestine.
This release profile treats gastrointestinal disorders by stabilizing the digestive system and alleviating the symptoms associated with disorders such as irritable bowel syndrome.
[0062] To treat a gastrointestinal disorder such as functional dyspepsia (classified as a gastro-duodenal disorder), the multiparticulate composition is formulated so that the peppermint oil is rapidly released after the multiparticulates pass through the stomach and the pylorus, over the course of about 0 to about 2 hours in order to deliver peppermint oil locally to the duodenum section of the small intestine to help stabilize the digestive system and/or alleviate the symptoms associated with functional dyspepsia. Preferably, 20% or less of the peppermint oil is released in the stomach and 20% or less of the peppermint oil is released in the jejunum and ileum sections of the small intestine (which follow the duodenum) and the colon.
[0063] To treat a gastrointestinal disorder such as inflammatory bowel disease, including ulcerative colitis or Crohn's disease), the multiparticulate composition is formulated so that the peppermint oil is rapidly released after the multiparticulates pass through the stomach and the small intestine, over the course of about 4 to about 6 hours, in order to deliver the peppermint oil locally to the colon to attenuate the inflammatory response and/or alleviate the symptoms associated with inflammatory bowel disease.
Preferably, 30% or less of the peppermint oil is released in the stomach and small intestine and greater than 70% of the peppermint oil is released in the first 2 hours after the multiparticulates reach the pH of the colon.
[0064] In a particularly preferred embodiment, the enteric coated cores of the multiparticulate composition release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N HC1 solution and, subsequently, no less than about 85% of the peppermint oil within about eight hours of being placed in a substantially neutral pH environment.
[0065] It should be understood that where this disclosure makes reference to treating a gastrointestinal disorder, that the terms "treat," "treating, or any other variation of the word "treat," include prevention of the gastrointestinal disorder.
[0066] The core formulation allows one to achieve a suitable release profile because the MCC acts as a release controlling polymer for peppermint oil. One skilled in the art will recognize that that the release rate of peppermint oil from the core can be adjusted by including a disintegrant, that actually functions as a disintegrant, or another conventional release controlling polymer.
[0067] A daily dose of a multiparticulate composition containing peppermint oil is about 20 mg to about 1200 mgs of peppermint oil, split into 2 or three doses per day. Each dosage form may contain between 10 mgs and 140 mgs of peppermint oil, more preferably, about 90-110 mg of peppermint oil.
[0068]
Doses of the multiparticulate composition may be administered sporadically when needed for treating acute inflammations of the gastrointestinal tract or may be administered as part of a long term regimen for treating GI
disorders such as irritable bowel syndrome, functional dyspepsia, gastroparesis, or inflammatory bowel disease. A
treatment subject may be a human or animal.
[0069] The enteric coated multiparticulates may be prepared into a suitable pharmaceutical or medical food dosage form such as a capsule, tablet or sachet, or are mixed with an acidic food vehicle and directly fed through a feeding tube. A
typical dosage form contains about 400 mg of the particulates, but, depending on the desired dosage, this amount may be adjusted.
Acidic food vehicles include citrus juices and foods such as, for example, apple sauce and apple juice.
[0070] The multiparticulate composition is preferably formulated to be administered enterally, such as orally or through a feeding tube, to a human or animal subject to ensure that the subject receives an effective amount of peppermint oil over the course of several hours after ingestion. The feeding tube may help with subjects that have achalasia, dysphagia, or another disorder that does not allow them to administer a capsule orally with water. Alternatively the multiparticulates can be sprinkled onto apple sauce for patients that cannot swallow larger sized capsules.
[0071] A
preferred method of making the multiparticulate composition is now described. The core is typically prepared by wet granulating the core materials into a wet mass, extruding the wet mass to form an extrudate, cutting the extrudate into a plurality of core pieces, and spheronizing the core pieces. The spheronized core pieces are then dried in a dryer such as a fluid bed dryer to remove the water. If desired the dried spheronized cores are then sieved to separate cores of different sizes.
[0072]
The dried spheronized cores are then coated with the proteinaceous subcoating material if desired. One way to apply the subcoating material to the cores is to prepare a subcoating solution and spray the subcoating solution onto the cores.
There are various conventional methods for doing this, but the preferred method is Wurster coating or fluid bed coating (top spray or bottom spray). The subcoating solution is subsequently allowed to dry over the cores, leaving each core coated with a thin, continuous proteinaceous film. If desired, the subcoated cores are sieved to separate them into different sizes.
[0073]
The enteric coating is then applied to the subcoated cores or directly to the cores if no subcoating is used. One means of applying the enteric coating is to spray it onto the subcoated cores.
There are various conventional methods for doing this, but the preferred method is Wurster coating or fluid bed coating.
The enteric coated particulates are subsequently dried.
During the enteric coating process; the cores are preferably heated in an environment that is about 20 degrees C
to about 50 degrees C to cure the enteric coating materials above their Tg.

[0 0 74] A
finish coating may be applied over the enteric coated particulates if desired.
One way to apply the finish coating is to spray it onto the enteric coated cores. There are various conventional methods for doing this, but the preferred method is Wurster coating or fluid bed coating.
[0075] A
more particular method of making a multiparticulate composition involves blending the peppermint oil, microcrystalline cellulose, hydrogel-forming polymer, and water to form the wet mass. The wet mass includes a hydrophobic phase containing the peppermint oil dispersed in a gel formed by the microcrystalline cellulose and a hydrophilic phase containing the hydrogel and water. The wet mass is extruded then extruded to form an extrudate and the extrudates is divided into individual wet cores. Water is removed from the hydrophilic phase in the wet cores to form dried cores. The enteric coating is then applied to the dried cores.
[0076]
Another method aspect of the invention is a method of treating a gastrointestinal disorder.
This method comprises administering to the subject a multiparticulate composition comprising a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing methylcellulose and an enteric coating over the individual cores.
[0077] The multiparticulate composition can be enterally administered through use of a conventional oral dosage form such as a tablet, caplet, capsule, or sachet, among others.
[0078] Another enteral means for administering the multiparticulate composition, either orally or via a tube, is by adding it to food. In this instance, the the multiparticulate composition is blended with an acidic food vehicle such as apple juice or another acidic vehicle that prevents premature release of the active ingredients and is then ingested by the subject..
Examples [0079] This section provides specific examples of the multiparticulate composition and method aspects of the invention.
These examples are provided to illuminate certain preferred aspects and embodiments of the invention, but the scope of the invention is not limited to what these examples teach.
Example 1: Preparation of a Multiparticulate Composition [0080]
The core was prepared using microcrystalline cellulose (MCC) commercially available under the name AVICELO PH 102 (FMC
Corp., Philadelphia, PA), methylcellulose commercially available under the name METHOCELO A15LV (Dow Chemical Co., Midland, MI), distilled peppermint oil, and USP purified water.
[0081]
33.25 kg MCC, 1.75 kg methylcellulose, and 15 kg peppermint oil were blended with water to form a wet mass. The wet mass was granulated in a high shear granulator.
The granulated wet mass was then extruded and spheronized.
The spheronized particles were subsequently dried in a fluid bed dryer to form uncoated cores. The drying temperature was about 16 degrees C.
[0082]
The uncoated cores were Wurster coated with 37 kg of a subcoating composition containing about 15% acid bone gelatin and 85% USP water and dried.
[0083]
The subcoated cores were Wurster coated with 31 kg of a 20% w/w enteric coating suspension containing KOLLICOATO MAE
30 DP, PlasACRYLC, T20, triethyl citrate USP, and purified water USP. The dry solids weight of amount KOLLICOATC, MAE 30 DP was approximately 5.4 kg. The dry solids weight of triethyl citrate was approximately 0.28 kg. The dry solids weight of PlasACRYLO

T20 was approximately 0.5 kg.
The enteric coated cores were then dried at about 40 degrees C.
[0084]
The enteric coated cores were Wurster coated with 26 kg of a finish coat solution containing about 10% w/w hydroxyl propyl methyl cellulose and 90% water USP and dried at about 40 degrees C.
Example 2: Stability Testing of the Multiparticulate Composition of Example 1 [0085]
The multiparticulate composition described in Example 1 was subsequently tested to ensure that the gelatin subcoating prevented the peppermint oil from evaporating and leaving the core when stored at elevated temperatures over a long period of time.
[0086] In the first set of experiments, we prepared capsules containing the multiparticulate composition and stored them at 40 degrees C and 75% relative humidity for four weeks.
Each week, we measured the amount of peppermint oil in a selection of the capsules. FIG. 1 shows the results of this study as a graph of the number of milligrams of L-menthol per capsule as a function of time. The results show that the amount of L-menthol in the capsules remained more or less constant at about 34 mg during the four week period.
This proves that the gelatin subcoating maintains the integrity of the core.
[0087] In the second set of experiments, we simulated the gastrointestinal environment and measured the dissolution profile of the multiparticulate composition to ensure that the enteric coating worked and that almost all of the peppermint oil would be released from the core within about 8.5 hours.
This was a conventional two stage dissolution study in which the sample was placed in an acidic medium (0.1 N HC1) for about two hours and subsequently placed in a neutral medium (pH = 6.8) for the remainder of the time.

[0088]
The results of this experiment are shown in FIG. 2 as the % release of peppermint oil, reported as the number of mgs of L-menthol over time. After two hours in the acidic medium, each of the samples tested had only released about 10% or less of the peppermint oil, indicating that the enteric coating was intact and worked normally. Over the following 6.5 hours in the neutral medium, the peppermint oil was gradually released from the core.
[0089]
Unless otherwise defined, all technical and scientific terms used herein are intended to have the same meaning as commonly understood in the art to which this invention pertains and at the time of its filing. Although various methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described. The skilled should understand that the methods and materials used and described are examples and may not be the only ones suitable for use in the invention.
The specification discloses typical preferred embodiments of the invention, and although specific terms are employed, the terms are used in a descriptive sense only and not for purposes of limitation.
The invention has been described in some detail, but it will be apparent that various modifications and changes can be made within the spirit and scope of the invention as described in the foregoing specification and in the claims.

Claims (26)

That which is claimed is:
1. A multiparticulate composition comprising a plurality of individual enteric coated cores, the cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel.
2. The multiparticulate composition of claim 1, further comprising a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings.
3. The multiparticulate composition of claim 2, wherein the continuous proteinaceous subcoating comprises a gelatin film adhered to the core.
4. The multiparticulate composition of claim 2, wherein the continuous proteinaceous subcoating comprises a dried proteinaceous gel.
5. The multiparticulate composition of claim 2, wherein the continuous proteinaceous subcoating is adapted to prevent the peppermint oil from mixing with the enteric coating.
6. The multiparticulate composition of claim 2, wherein the enteric coating has a glass transition temperature higher than a standard boiling point of the peppermint oil.
7. The multiparticulate composition of claim 1, wherein the enteric coated cores release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N

HCl solution and, subsequently, no less than about 85% of the peppermint oil within about eight hours of being placed in a substantially neutral pH environment.
8. The multiparticulate composition of claim 1, wherein the enteric coated cores are spheroidal and not more than 3 mm in diameter.
9. A multiparticulate composition comprising a plurality of individual enteric coated cores containing about 15% w/w to about 40% w/w peppermint oil, about 35% w/w to about 75% w/w microcrystalline cellulose, and about 2% w/w to about 15% w/w methylcellulose, wherein the % w/w is the % w/w of the enteric coated cores.
10. The multiparticulate composition of claim 9, further comprising a continuous proteinaceous subcoating layer covering the cores and separating the cores from their respective enteric coatings.
11. The multiparticulate composition of claim 10, wherein the continuous proteinaceous subcoating comprises a gelatin film adhered to the core.
12. The multiparticulate composition of claim 10, wherein the continuous proteinaceous subcoating comprises a dried proteinaceous gel.
13. The multiparticulate composition of claim 10, wherein the continuous proteinaceous subcoating is adapted to prevent the peppermint oil from mixing with the enteric coating.
14. The multiparticulate composition of claim 10, wherein the enteric coating has a glass transition temperature higher than a standard boiling point of the peppermint oil.
15. The multiparticulate composition of claim 10, wherein the enteric coated cores release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N
HCl solution and, subsequently, no less than about 85% of the peppermint oil within about eight hours of being placed in a substantially neutral pH environment.
16. The multiparticulate composition of claim 9, wherein the enteric coated cores are spheroidal and not more than 3 mm in diameter.
17. A method of making a multiparticulate composition, the method comprising:
blending peppermint oil, microcrystalline cellulose, a hydrogel forming polymer, and water to form a wet mass including a hydrophobic phase containing the peppermint oil dispersed in a microcrystalline cellulose gel and a hydrophilic phase containing the hydrogel forming polymer and water;
extruding the wet mass to form an extrudate;
dividing the extrudate into individual wet cores;
removing water from the hydrophilic phase in the wet cores to form dried cores; and applying an enteric coating to the dried cores.
18. The method of claim 17, further comprising coating the dried cores with a liquid proteinaceous material and drying the liquid proteinaceous material to form sub-coated cores prior to applying the enteric coating.
19. The method of claim 18, wherein the liquid proteinaceous material comprises gelatin.
20. The method of claim 18, wherein the liquid proteinaceous material is a solution containing at least about 50% gelatin.
21. The method of claim 18, wherein coating the dried cores with a liquid proteinaceous material comprises spraying the liquid proteinaceous material onto the dried cores.
22. The- method of claim 17, wherein the enteric coated core is spheroidal and not more than 3 mm in diameter.
23. The method of claim 17, wherein removing water from the hydrophilic phase in the wet cores to form dried cores is achieved without substantially removing peppermint oil.
24. A method of treating a gastrointestinal disorder in a subject, the method comprising administering to the subject a multiparticulate composition comprising a plurality of individual enteric coated cores, the cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel.
25. The method of claim 24, wherein administering is performed enterally.
26. The method of claim 24, wherein the multiparticulate composition is blended with an acidic vehicle prior to being administered.
CA2881992A 2013-04-23 2013-09-23 Enteric coated multiparticulate controlled release peppermint oil composition and related methods Active CA2881992C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361815073P 2013-04-23 2013-04-23
US61/815,073 2013-04-23
US201361880294P 2013-09-20 2013-09-20
US61/880,294 2013-09-20
PCT/US2013/000217 WO2014175852A1 (en) 2013-04-23 2013-09-23 Enteric coated multiparticulate controlled release peppermint oil composition and related methods

Publications (2)

Publication Number Publication Date
CA2881992A1 true CA2881992A1 (en) 2014-10-30
CA2881992C CA2881992C (en) 2016-11-22

Family

ID=51792243

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2909591A Active CA2909591C (en) 2013-04-23 2013-09-23 Enteric coated multiparticulate composition with proteinaceous subcoat
CA2881992A Active CA2881992C (en) 2013-04-23 2013-09-23 Enteric coated multiparticulate controlled release peppermint oil composition and related methods

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2909591A Active CA2909591C (en) 2013-04-23 2013-09-23 Enteric coated multiparticulate composition with proteinaceous subcoat

Country Status (21)

Country Link
US (7) US8895086B2 (en)
EP (2) EP2872123B1 (en)
JP (3) JP5869735B2 (en)
KR (2) KR101616679B1 (en)
CN (2) CN105263480B (en)
AU (2) AU2013387678B2 (en)
BR (2) BR112015026283B1 (en)
CA (2) CA2909591C (en)
CY (1) CY1121582T1 (en)
DK (1) DK2988824T3 (en)
ES (2) ES2706152T3 (en)
HR (1) HRP20190210T1 (en)
HU (1) HUE042996T2 (en)
LT (1) LT2988824T (en)
MX (2) MX344705B (en)
PL (2) PL2872123T3 (en)
PT (2) PT2872123T (en)
RS (1) RS58325B1 (en)
RU (2) RU2647462C2 (en)
SI (1) SI2988824T1 (en)
WO (3) WO2014175916A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
NZ745682A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AU2013387678B2 (en) 2013-04-23 2015-04-16 Sociétés des Produits Nestlé S.A. Enteric coated multiparticulate controlled release peppermint oil composition and related methods
TN2018000069A1 (en) 2015-09-01 2019-07-08 First Wave Biopharma Methods and compositions for treating conditions associated with an abnormal inflammatory responses
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
BR112018072795A2 (en) 2016-05-06 2019-04-30 Physician's Seal, LLC valerian composition and related methods
KR102568459B1 (en) 2016-10-26 2023-08-22 에스엘 주식회사 The Apparatus For Controlling Vehicle Lamp
CN107049992A (en) * 2017-05-31 2017-08-18 盛林 A kind of EGCG micro pill capsules and preparation method thereof
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109864982A (en) * 2019-03-22 2019-06-11 大连医诺生物股份有限公司 Epigallo-catechin gallate (EGCG) microcapsule powder and preparation method thereof
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
WO2021188564A1 (en) 2020-03-16 2021-09-23 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
KR102608047B1 (en) * 2020-12-29 2023-12-01 주식회사 우제아이엠 Balanced nutrition included food composition for preventing or improving reflux esophageal disease or functional dyspepsia
EP4274554A1 (en) * 2021-01-08 2023-11-15 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating central nervous system disorders

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1811777A (en) 1924-06-19 1931-06-23 Howards & Sons Ltd Process for making synthetic menthol
US2366749A (en) 1942-08-29 1945-01-09 Burton T Bush Inc Process for making synthetic menthol
US3515781A (en) 1967-10-12 1970-06-02 Johnson & Johnson Cold capsule
JPS521819A (en) 1975-06-05 1977-01-08 Nippon Tokushu Toryo Kk Acoustic lining material for vehicle
US4080552A (en) 1976-09-22 1978-03-21 Facet Enterprises, Inc. Hybrid blocking oscillator for an electromagnetic fuel pump
EP0015334B1 (en) 1977-08-04 1982-05-19 J.B. Tillott Limited Carminative preparations containing peppermint oil or its active components
JPS61176535A (en) * 1985-01-31 1986-08-08 Morishita Jintan Kk Enteric drug preparation
JPS62226926A (en) * 1986-03-27 1987-10-05 Teisan Seiyaku Kk Long acting complex granule
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
IT1243193B (en) 1990-08-10 1994-05-24 Medea Res Srl ORAL PHARMACEUTICAL COMPOSITIONS BASED ON MELATONIN
US5418010A (en) * 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
US5169754A (en) * 1990-10-31 1992-12-08 Coulter Corporation Biodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making same
DK0518468T3 (en) 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatonin-containing compositions
JP3015607B2 (en) 1991-10-16 2000-03-06 信越化学工業株式会社 Communication disruption method using pheromone preparation
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5397573A (en) 1993-06-04 1995-03-14 The Procter & Gamble Company Laxative compositions
US5417010A (en) * 1993-08-09 1995-05-23 Ecer; Gunes M. Light weight seeding sheet
DE69432186T2 (en) 1993-11-18 2004-05-06 Nippon Shinyaku Co., Ltd. METHOD FOR PRODUCING STABLE MEDICINAL PRODUCTS
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
KR20010012402A (en) 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. Stable oral pharmaceutical dosage forms
JPH1147581A (en) 1997-07-30 1999-02-23 Takasago Internatl Corp Slow release capsule and its preparation
FR2771292B1 (en) 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques TIAGABINE-CONTAINING SPHEROIDS, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6673126B2 (en) 1998-05-14 2004-01-06 Seiko Epson Corporation Multiple chamber fabrication equipment for thin film transistors in a display or electronic device
DK2263660T3 (en) 1998-05-18 2018-01-02 Takeda Pharmaceuticals Co Orally disintegrating tablets.
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
JP2000247870A (en) 1999-02-24 2000-09-12 Isp Japan Kk Solid pharmaceutical preparation suppressed in whisker deposition and its production
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
DE60025201T2 (en) 1999-06-09 2006-06-29 Mochida Pharmaceutical Co. Ltd. SYSTEM FOR DRUG RELIEF IN LOWER DIGESTIVE STRUCTURE
AU781048B2 (en) 1999-09-02 2005-05-05 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6458384B2 (en) 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
ATE313375T1 (en) 2000-03-04 2006-01-15 Cognis Ip Man Gmbh MICRO CAPSULES
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
US6423349B1 (en) 2000-08-24 2002-07-23 Baxter International, Inc. Therapeutic nutrient composition for pre and post elective surgery
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
FR2816507B1 (en) 2000-11-16 2003-02-28 Ethypharm Lab Prod Ethiques MICROGRANULES BASED ON ACTIVE PRINCIPLE, PROCESS FOR THE MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAID MICROGRANULES
US20020114832A1 (en) 2000-12-11 2002-08-22 Dr. Willmar Schwabe Gmbh & Co. Pharmaceutical preparation comprising peppermint oil and caraway oil in delayed release form
US20030143272A1 (en) 2001-03-14 2003-07-31 Waterman Kenneth C. Pharmaceutical tablet and process for making thereof
JP4184278B2 (en) 2001-11-22 2008-11-19 森下仁丹株式会社 Non-gelatin capsule coating composition and capsule using the same
AU2003210598A1 (en) 2002-01-18 2003-09-04 Hypnion Inc Treatment of sleep disorders using sleep target modulators
JP4429590B2 (en) * 2002-02-08 2010-03-10 株式会社協和ウェルネス Ubiquinone-containing water-soluble composition
DK1578350T3 (en) * 2002-03-26 2009-08-10 Euro Celtique Sa Composition with gel coating with depot effect
US7115282B2 (en) 2002-04-17 2006-10-03 Salvona Ip Llc Multi component controlled release system for anhydrous cosmetic compositions
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
DE10224087A1 (en) 2002-05-31 2003-12-11 Symrise Gmbh & Co Kg Compacted menthol
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
PT2772250T (en) * 2002-10-01 2017-01-02 Banner Life Sciences Llc Enteric composition for the manufacture of soft capsule wall
FR2845289B1 (en) 2002-10-04 2004-12-03 Ethypharm Sa SPHEROIDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS.
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
DE60318237T2 (en) 2002-10-24 2008-12-18 Immupharm A/S PHARMACEUTICAL COMPOSITIONS CONTAINING FLAVONOIDS AND MENTHOL
EP1585505A1 (en) 2002-10-24 2005-10-19 Micap Plc. Targeted delivery
AU2004226443A1 (en) 2003-03-26 2004-10-14 Wm. Wrigley Jr. Company Confectionery with fast flavor release jacket coating
US6737470B1 (en) 2003-04-04 2004-05-18 Bridgestone Corporation Curable sealant composition
US8389008B2 (en) * 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
AU2004308962A1 (en) 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
US20050181047A1 (en) 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
US20050202079A1 (en) 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
RS52233B (en) * 2004-05-07 2012-10-31 Nycomed Gmbh Farmaceutical dosage form comprising pellets as well as its manufacturing process
US8383154B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
DE102004036437A1 (en) 2004-07-27 2006-03-23 Röhm GmbH & Co. KG Multiparticulate dosage form for sparingly soluble active ingredients, as well as a method for producing the dosage form
ITMI20041689A1 (en) 2004-09-01 2004-12-02 Bojidar Mihaylov Stankov NEW FORMULATIONS OF CONTROLLED RELEASE CONTAINING 5-HYDROXYTYRIPHOPHANE AND TRIPTOPHAN
AR052142A1 (en) * 2004-11-18 2007-03-07 Bristol Myers Squibb Co ENTERIC COATED PEARL THAT INCLUDES IXABEPILONA, AND PREPARATION AND ADMINISTRATION OF THE SAME
US8574544B1 (en) 2005-01-04 2013-11-05 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8535640B1 (en) 2005-01-04 2013-09-17 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8337811B1 (en) 2005-01-04 2012-12-25 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8361439B1 (en) 2005-01-04 2013-01-29 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
DE602006011288D1 (en) 2005-03-16 2010-02-04 Symrise Gmbh & Co Kg MENTHOLDING SOLIDS COMPOSITION
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
EP1868580A1 (en) 2005-03-29 2007-12-26 Evonik Röhm GmbH Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
US20060257469A1 (en) 2005-04-05 2006-11-16 Bulka Yochanan R Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase
WO2006118017A1 (en) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. Stabilized composition
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US8784851B2 (en) 2005-07-28 2014-07-22 University Of Hull Topical formulations containing sporopollenin
US20070048366A1 (en) 2005-08-26 2007-03-01 Jen-Chi Chen Gelatin-based coatings having improved durability
JP2007197378A (en) 2006-01-27 2007-08-09 Kowa Co Sugar-coated preparation
JP2009541337A (en) * 2006-06-19 2009-11-26 マクニール−ピーピーシー・インコーポレーテツド Enteric coated particles containing active ingredients
EP2486910A3 (en) * 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
JP5201819B2 (en) 2006-11-22 2013-06-05 エスエス製薬株式会社 Solid composition
TW200831140A (en) 2006-11-28 2008-08-01 Wyeth Corp Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution
KR20090091321A (en) 2006-11-28 2009-08-27 마리누스 파마슈티컬스 Nanoparticulate formulations and methods for the making and use thereof
US20080139510A1 (en) 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP1953625A1 (en) 2007-02-02 2008-08-06 Melik Gencel Peripheral inputting device for computers
MX2009010878A (en) 2007-04-11 2010-03-26 John A Mccarty Melatonin tablet and methods of preparation and use.
WO2008134807A1 (en) 2007-05-04 2008-11-13 The University Of Sydney Method for manufacturing a porous polymer matrix
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
JP2010533159A (en) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ Compound 947
US8048921B2 (en) 2007-09-18 2011-11-01 Ronald Kramer Amino acid compounds
EP2205231A1 (en) 2007-10-01 2010-07-14 NeuroSearch A/S Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound
GB0724550D0 (en) * 2007-12-18 2008-01-30 Univ Hull Formulations
US20090238905A1 (en) * 2008-03-20 2009-09-24 Symrise, Inc. Inflammation reducing action of synergistic mixtures of bisabolol and ginger extracts
US20090246301A1 (en) * 2008-03-31 2009-10-01 Ehrenpreis Ben Z Method for treating irritable bowel syndrome and other functional gastrointestinal disorders
DE102008023345B4 (en) 2008-05-13 2014-12-04 Lts Lohmann Therapie-Systeme Ag Film-like preparation with oily substances for oral administration
CN101596166B (en) 2008-06-04 2011-08-17 永信药品工业(昆山)有限公司 Aspirin enteric-coated pellet
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
CA2753444A1 (en) * 2009-02-23 2010-08-26 Gopi Venkatesh Controlled-release compositions comprising a proton pump inhibitor
CA2761538A1 (en) 2009-05-20 2010-12-23 Lingual Consegna Pty Ltd Buccal and/or sublingual therapeutic formulation
EP2305742B1 (en) 2009-10-01 2017-02-22 Symrise AG Spherical core-shell-particle
US9205395B2 (en) 2009-10-15 2015-12-08 Encapsys, Llc Encapsulation
US9050264B2 (en) 2009-11-07 2015-06-09 University Of Iowa Research Foundation Cellulose capsules and methods for making them
WO2011111027A2 (en) 2010-03-11 2011-09-15 Dexcel Pharma Technologies Ltd. Oral dispersible delayed release tablet formulation
WO2011146078A1 (en) 2010-05-21 2011-11-24 Board Of Regents, The University Of Texas System Encapsulated particles for enteric release
JP2010189443A (en) 2010-06-07 2010-09-02 Ss Pharmaceut Co Ltd Volatilization-preventing solid preparation and manufacturing method thereof
CN103826614B (en) 2010-11-16 2018-04-13 普乐维美北美公司 Enteric coated sodium pyrosulfite poultry and livestock feed additive for vomitoxin removing toxic substances
BE1019142A3 (en) * 2011-01-21 2012-03-06 Vesale Pharma S A MICROENCAPSULATED PROBIOTIC SUBSTANCE.
PL2672981T3 (en) * 2011-02-11 2018-09-28 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
WO2012162492A1 (en) 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
US20120301546A1 (en) * 2011-05-26 2012-11-29 Hassan Emadeldin M Acid-resistant soft gel compositions
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
WO2012170488A1 (en) * 2011-06-07 2012-12-13 Zx Pharma, Llc Multiparticulate s-adenosylmethionine compositions and related methods
DE202012000910U1 (en) * 2012-01-20 2013-01-21 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Systemic dosage forms with controlled release and improved stability
JP6227546B2 (en) 2012-10-26 2017-11-08 田辺三菱製薬株式会社 Method for inhibiting menthol whisker precipitation
US20140178468A1 (en) 2012-12-24 2014-06-26 Ranbaxy Laboratories Limited Multiparticulate extended-release composition of mesalamine
AU2013387678B2 (en) * 2013-04-23 2015-04-16 Sociétés des Produits Nestlé S.A. Enteric coated multiparticulate controlled release peppermint oil composition and related methods
JP2015024986A (en) 2013-06-20 2015-02-05 大正製薬株式会社 Solid preparations

Also Published As

Publication number Publication date
US20160038429A1 (en) 2016-02-11
HUE042996T2 (en) 2019-07-29
PT2872123T (en) 2017-03-15
EP2872123A4 (en) 2016-01-20
US8895086B2 (en) 2014-11-25
BR112015006499A2 (en) 2017-07-04
JP2016517867A (en) 2016-06-20
US9717696B2 (en) 2017-08-01
AU2013387678A1 (en) 2015-02-26
US20160022597A1 (en) 2016-01-28
WO2014175852A1 (en) 2014-10-30
JP6105761B2 (en) 2017-03-29
PT2988824T (en) 2019-01-30
US20220071912A1 (en) 2022-03-10
MX2015014915A (en) 2016-03-07
EP2872123A1 (en) 2015-05-20
JP5869735B2 (en) 2016-02-24
CA2881992C (en) 2016-11-22
EP2872123B1 (en) 2017-01-04
HRP20190210T1 (en) 2019-04-05
US20140314860A1 (en) 2014-10-23
PL2872123T3 (en) 2017-06-30
CA2909591C (en) 2017-03-28
AU2013387667B2 (en) 2016-08-04
WO2014175917A1 (en) 2014-10-30
RU2015149770A (en) 2017-05-26
DK2988824T3 (en) 2019-01-14
JP2016056189A (en) 2016-04-21
EP2988824A4 (en) 2017-02-01
US20150050352A1 (en) 2015-02-19
EP2988824B1 (en) 2018-11-07
EP2988824A1 (en) 2016-03-02
KR101616679B1 (en) 2016-04-28
US20190307701A1 (en) 2019-10-10
CN105263480A (en) 2016-01-20
BR112015026283B1 (en) 2023-04-25
US10420730B2 (en) 2019-09-24
AU2013387667A1 (en) 2015-10-29
RU2647462C2 (en) 2018-03-15
US11826475B2 (en) 2023-11-28
CA2909591A1 (en) 2014-10-30
JP2015534582A (en) 2015-12-03
BR112015026283A2 (en) 2017-09-05
MX2015005913A (en) 2015-09-08
WO2014175917A8 (en) 2014-12-18
CN105263480B (en) 2018-08-28
RS58325B1 (en) 2019-03-29
WO2014175916A1 (en) 2014-10-30
US9572782B2 (en) 2017-02-21
KR101787225B1 (en) 2017-10-18
KR20150042233A (en) 2015-04-20
CN105142726B (en) 2020-02-07
AU2013387678B2 (en) 2015-04-16
KR20150139961A (en) 2015-12-14
US9192583B2 (en) 2015-11-24
SI2988824T1 (en) 2019-02-28
ES2616701T3 (en) 2017-06-14
CY1121582T1 (en) 2020-05-29
RU2606593C1 (en) 2017-01-10
CN105142726A (en) 2015-12-09
US20150044294A1 (en) 2015-02-12
LT2988824T (en) 2019-02-25
PL2988824T3 (en) 2019-04-30
MX344705B (en) 2017-01-04
ES2706152T3 (en) 2019-03-27
US11207273B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
CA2881992C (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US9707260B2 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US11207276B2 (en) Multiparticulate L-menthol formulations and related methods
AU2015203894B2 (en) Enteric coated multiparticulate controlled release peppermint oil composition and related methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150213